MDM2 and cancer: As confirmed by a potent and selective MDM2-TP53 small-molecule antagonist, Idasanutlin, TP53 mutations is predictive of anti-TP53-drug resistance [59], while the treatment of cancer cells expressing functional TP53 resulted in the concurrent transcriptional activation of TP53 downstream genes, cell cycle arrest, and cell death [39].